RA Capital Management PRTO Position
Exited5-Fund ConvergenceRA Capital Management exited their position in Protara Therapeutics, Inc. (PRTO) in Q3 2025, after holding the stock for 6 quarters.
The position was first reported in Q2 2024 and has been tracked across 6 quarterly 13F filings.
PRTO is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Choline Chloride for Injection in 442 days (Jun 30, 2027), making the timing of RA Capital's position particularly relevant.
About Protara Therapeutics, Inc.
The RCN Pareto Strategic Allocation ETF (the Fund) seeks long-term capital appreciation.
Full company profile →RA Capital Management PRTO Position History
Frequently Asked Questions
Does RA Capital Management own PRTO?
No. RA Capital Management exited their position in Protara Therapeutics, Inc. (PRTO) in Q3 2025. They previously held the stock for 6 quarters.
How many hedge funds own PRTO?
5 specialist biotech hedge funds currently hold PRTO, including Driehaus Capital, Baker Bros. Advisors, OrbiMed Advisors and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy PRTO?
RA Capital Management's position in PRTO was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's PRTO position increasing or decreasing?
RA Capital Management completely exited their PRTO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PRTOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →